$52.300
+1.872 (+3.58%)收盘时
TVTX 资讯
TVTX 事件
Travere Therapeutics Secures New Patent for Kidney Disease Treatment
Travere Therapeutics announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI in focal segmental glomerulosclerosis. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in FSGS into October 2037. The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere expects to submit the issued patent for listing in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations promptly following grant. In August, the USPTO granted a separate U.S. patent to the Company covering certain methods of using sparsentan in IgA nephropathy.
Travere Therapeutics CEO Eric Dube Resigns, Bradley Campbell to Succeed
Travere Therapeutics announced that Eric Dube, Ph.D., has made the decision to step down as president and chief executive officer to "focus on his health and family." The company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dube as president and chief executive officer and a member of the Board, effective December 1, 2026. Dube will continue to serve as president and chief executive officer until that date and will remain employed by the Company as executive advisor through February 15, 2027, to support an orderly transition. "Leading Travere has been the greatest privilege of my career," said Dr. Dube. "When I became CEO almost eight years ago, I believed we had an opportunity and a responsibility to deliver meaningful innovation to rare disease communities that had waited far too long for better therapies. Together, our team has brought important medicines to patients, built a diverse pipeline and achieved a milestone particularly meaningful to me - the first approved medicine for FSGS. My own experiences with rare disease have also given me a profound appreciation for health, family and time. After considerable reflection, I've decided this is the right moment for me to step away from full-time operating roles and devote greater attention to those priorities. I have made that decision with enormous confidence in Travere's future, its leadership team and in Bradley. He has the unique experience, values and commitment to patients to lead this company through its next chapter, and I look forward to supporting a seamless transition."
Digital Turbine Shares Rise 24.3% After Earnings
Stock futures were mixed following this week's already sharp gains after another slate of big earnings reports. While SpaceX slipped after its first report as a public company, gains from Booking, Arista, and others weighed on futures. Crude oil futures were also lower amid optimism over a potential U.S.-Iran deal to reopen the Strait of Hormuz.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Digital Turbineup 24.3%Travere Therapeuticsup 12.4%Arista Networksup 9.2%Ultragenyxup 6.4%Bookingup 5.7%Wynn Resortsup 5.5%Paylocityup 3.4%ALSO HIGHER -Sight Sciencesup 9.6% after receiving FDA 510clearance of the Omni Ultra Surgical SystemDOWN AFTER EARNINGS -Teradatadown 18.4%ViaSatdown 9.5%Chemoursdown 9.4%Match Groupdown 9.1%Pinterestdown 9.1%AMDdown 8.7%Lucid Groupdown 7.8%DaVitadown 7.3%SpaceXdown 7.2%Lattice Semiconductordown 6.5%Coupangdown 6.1%
Travere Therapeutics Chief Research Officer Plans to Retire in February 2027
Travere Therapeutics "announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO."
Travere Therapeutics FILSPARI Shows Positive Long-Term Results in FSGS Treatment
Travere Therapeutics announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension of FILSPARI in the treatment of focal segmental glomerulosclerosis. Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI at the start of the OLE subsequently demonstrated rapid and sustained reductions in proteinuria similar to those who initiated FILSPARI at the beginning of the double-blind period. The results were presented at the European Renal Association 2026 Congress in Glasgow, Scotland June 3-6. The Phase 3 DUPLEX Study is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial that assessed the efficacy and safety of FILSPARI in patients with biopsy-proven or genetic FSGS compared to maximum labeled dose irbesartan for up to 108 weeks. At the end of the double-blind period, all patients were eligible to enroll in the open-label extension portion of the trial following a 4-week washout period and receive FILSPARI for up to three additional years. During the DUPLEX double-blind period, patients treated with FILSPARI achieved higher rates of complete and partial remission compared to maximum labeled dose irbesartan. Complete remission (urine protein-to-creatinine ratio, UPCR less than0.3 g/g) was achieved by 18.5% of FILSPARI-treated patients compared to 7.5% of those who received irbesartan, while partial remission (UPCR less than1.5 g/g) was achieved by 69.0% and 50.8% of patients, respectively. Following transition to the OLE, patients who remained on FILSPARI maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Among these patients, 37.5% achieved complete remission at any time across the double-blind or OLE period, and 87.5% achieved partial remission. Patients who transitioned from irbesartan to FILSPARI in the OLE after washout experienced rapid and sustained reductions in proteinuria, consistent with the reductions observed among patients who began FILSPARI during the double-blind period. Among these patients, 28.9% achieved complete remission at any time across the double-blind or OLE period, and 74.6% achieved partial remission. FILSPARI was generally well tolerated during the long-term OLE follow-up in the study with a safety profile consistent with previous findings.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。